|
| 产品描述 |
| Dabrafenib, also known as GSK2118436 , is an orally bioavailable inhibitor of B-raf (BRAF) protein with potential antineoplastic activity. Dabrafenib selectively binds to and inhibits the activity of B-raf, which may inhibit the proliferation of tumor cells which contain a mutated BRAF gene. B-raf belongs to the the raf/mil family of serine/threonine protein kinases and plays a role in regulating the MAP kinase/ERKs signaling pathway, which may be constitutively activated due to BRAF gene mutations. On May 29, 2013, FDA approved this drug. |
| 化学结构 |
 |
| 化学名称 |
| N-(3-(5-(2-aminopyrimidin-4-yl)-2-(tert-butyl)thiazol-4-yl)-2-fluorophenyl)-2,6-difluorobenzenesulfonamide |
| SMILES Code |
| O=S(C1=C(F)C=CC=C1F)(NC2=CC=CC(C3=C(C4=NC(N)=NC=C4)SC(C(C)(C)C)=N3)=C2F)=O |
| 基本信息 |
产品编号:XM058
产品名称:Dabrafenib
别名:GSK2118436A ( Dabrafenib ); GSK 2118436A; GSK-2118436A; GSK2118436B ( Dabrafenib Mesylate ); GSK-2118436B; GSK 2118436B. Trade name: Tafinlar.
CAS#:1195765-45-7 (free base)
分子式:C23H20F3N5O2S2
精确分子量:519.10105
分子量:519.56
纯度:>98%
|
| 物化性质 |
外观: 类白色固体粉末
纯度: >98%
运输信息: 非危险化学品，适于常温或冰袋运输。
储存条件: 低温，干燥，避光。
溶解性: 溶于DMSO, 不溶于水
储存期限:3年 -20℃固体储存
2 年 -80℃溶液储存 |
该产品只供科研使用，不能给病人提供。
|
|
|
